JAK1 and atopic eczema: In light of these data, we extended our analyses to atopic dermatitis, a second, common, chronic inflammatory skin disease, by examining IL-19 levels in patients enrolled in a phase 2 study for the JAK1/2 inhibitor baricitinib.